trending Market Intelligence /marketintelligence/en/news-insights/trending/ozsnmyorfnrej0lw58jgmq2 content esgSubNav
In This List

ChemoCentryx expands commercial agreement with Vifor

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ChemoCentryx expands commercial agreement with Vifor

ChemoCentryx Inc. sold the Chinese commercialization rights to its kidney disease medicines CCX140 and avacopan to Vifor Pharma AG for an up-front cash payment of $21.5 million.

Switzerland's Vifor will also pay a royalty on the sales of the drugs, once they are commercialized.

Mountain View, Calif.-based ChemoCentryx continues to retain the U.S. commercialization rights to the medicines.

The companies previously agreed to partner on the development of the drugs.